RecruitingPhase 2NCT06691217

Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

Sponsor

Massachusetts General Hospital

Enrollment

120 participants

Start Date

Mar 24, 2026

Study Type

INTERVENTIONAL

Conditions

ASCVD Vascular Inflammation ASCVD Management

Summary

The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coronary artery disease, including those with and without clonal hematopoiesis driven by mutations in TET2.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called CANAKINUMAB (ILARIS®) and a drug called Saline (NaCl 0,9 %) (placebo) for people with ascvd, ascvd management, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCANAKINUMAB (ILARIS®)

Participants with and without TET2 CHIP will receive 150mg of canakinumab every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.

DRUGSaline (NaCl 0,9 %) (placebo)

Participants with and without TET2 CHIP will receive placebo injection every 3 months for 4 doses as part of the randomized clinical trial part of this proposal.